Full Press Release Details
REGENERON COMPLETES 12-MONTH EFFICACY PHASE OF AXOKINE(R) PHASE III PIVOTAL TRIAL FOR THE TREATMENT OF OBESITY.
REGN
REGENERON COMPLETES 12-MONTH EFFICACY PHASE OF AXOKINE(R) PHASE III PIVOTAL TRIAL FOR THE TREATMENT OF OBESITY
Key Takeaway: REGENERON COMPLETES 12-MONTH EFFICACY PHASE OF AXOKINE(R) PHASE III PIVOTAL TRIAL FOR THE TREATMENT OF OBESITY
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+35%
120-day peak, hindsight
Typical move
2.6%
average across 15 past catalysts
Lead asset
VEGF Trap-Eye
Phase 1 · Diabetic Macular Edema